A systematic review of dermal fillers for age‐related lines and wrinkles

Sturm, Lana; Cooter, Rodney D.; Mutimer, Keith L.; Graham, John C.; Maddern, Guy J.

doi:10.1111/j.1445-2197.2010.05351.x

Cited by 19 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This complication occurs in 0.2%-8% of cases. 28 Imaging can be useful for delineating the extent of the excess material, which can be identified by contour deformity of the overlying skin (Fig 10). Patients who present for imaging evaluation of skin bulges may be reluc- tant to disclose a history of facial augmentation, making the diagnosis somewhat less straightforward.…”

Section: Complicationsmentioning

confidence: 99%

“…This complication is often disfiguring, with limited mobility of the mimetic muscles, and is difficult to treat even via steroid injections and surgical excision. 28 Foreign-body granulomas are considered rare complications of FDA-approved injectable facial fillers, with incidences ranging from 0.02% to 1%, and tend to develop several months to years after injection. 34,35 Silicone oil has a relatively high incidence of foreign-body granuloma formation, though this adverse reaction most commonly results from the use of preparations that are not "medical grade" silicone.…”

Section: Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Imaging Features of Midface Injectable Fillers and Associated Complications

Ginat

Schatz

2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

Section: Complicationsmentioning

confidence: 99%

Section: Complicationsmentioning

confidence: 99%

Imaging Features of Midface Injectable Fillers and Associated Complications

Ginat

Schatz

2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

“…The correction of the effects of facial aging should be directed primarily to the correction of volume as, without it, the patient continues with an aged appearance. Skin fillers have become popular for this purpose because are minimally invasive and durable, showing no potential comorbidities as a surgical procedure (Smith et al, 2007;Dayan & Bassichis, 2008;Vargas et al, 2009;Sundaram et al, 2010;Sturm et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Composite synthetic hydroxyapatite 30%, in two physical states, as dermal filler

et al. 2013

View full text Add to dashboard Cite

RESUMO Compósito de hidroxiapatita sintética 30%, em dois estados físicos, como preenchedor de relevo cutâneoObjetivou-se avaliar a resposta tecidual, após implantação de hidroxiapatita sintética 30% (HAP-91 ® ), em dois estados físicos, para preenchimento cutâneo. Foram utilizados 18 coelhos da raça Nova Zelândia, distribuídos aleatoriamente em dois grupos ® fluida e viscosa) e, posteriormente, divididos em três subgrupos, de acordo com o período pós-implante, em oito, 21 e 49 dias. Em cada grupo foi implantado 1,0 mL de HAP-91 ® , fluida ou viscosa, no tecido subcutâneo, 1 cm cranial à crista da escápula direita. Foi realizada a mensuração da espessura cutânea, imediatamente antes e durante 15 dias após a implantação do compósito. Avaliações de sensibilidade dolorosa foram realizadas, atribuindo-se os escores: 0 -quando o animal permitiu o toque e não manifestou reação; 1 -quando permitiu o toque, mas manifestou reação de dor, como aumento da frequência respiratória ou tentativa de fuga; 2 -quando não permitiu o toque. Aos oito, 21 e 49 dias, foi realizada a biópsia da região implantada. Não foi observada diferença entre a espessura cutânea dos animais (p > 0,05) e todos os animais receberam escore 0 para sensibilidade dolorosa. Na análise histológica, não foi notado processo inflamatório evidente. Houve predomínio de células mononucleares, nas amostras de oito dias, e uma organização tecidual ao redor do biomaterial, com tendência ao encapsulamento. A HAP-91 ® , tanto fluida quanto viscosa, é biocompatível e indicada para o preenchimento cutâneo.Palavras-chave: implante cutâneo, compósito, medicina estética. The aim of this study was to evaluate the response to the implantation of synthetic hydroxyapatite 30% (HAP-91 ® ) in different physical states as dermal filler. Eighteen New Zealand rabbits were used, distributed randomly into two equal groups and then divided into three groups according to the postoperative period at 8, 21 and 49 days. One mL of HAP-91 ® , fluid and viscous, was implanted in the subcutaneous tissue, 1 cm proximal to the cranial crest of the right scapula. The thickness of the skin was measured before and after implantation and for the following 15 days. Pain sensitivity assessment was conducted, assigning the following scores: 0 -when the animal allowed the touch of the implant area and expressed no signs of pain; 1 -when the animal allowed the touch, but pain reaction occurred, like increase of the respiratory rate or attempt to escape; 2 -when the animal did not allow the touch to the implanted area. At 8, 21 and 49 days, biopsy of the implanted area was performed. No difference was observed between the thickness of the skin (p>0.05) and all animals received a score 0 for soreness. Histological analysis did not reveal any obvious inflammatory process, showing a predominance of mononuclear cells in samples of eight days and tissue organization around the biomaterial with a tendency to encapsulation. The results indicate that HAP-91 ® , both viscous and fluid, is biocompatible...

show abstract

“…Dependiendo del momento en que ocurran, las complicaciones se dividen en inmediatas, tempranas y tardías, según suceden durante los primeros dos días, entre los 3 y 14 días, o tras dos semanas postinyección; respectivamente 6 . Las complicaciones tardías incluyen inflamación crónica, granulomas, infecciones por Mycobacterium spp., necrosis, osteomielitis crónica y muerte 7 . A diferencia de las infecciones asociadas al empleo de prótesis, la remoción completa de los materiales inyectables puede no ser posible y requieren de terapias más prolongadas 8 .…”

Section: Discussionunclassified